Cationic lipids and methods for the delivery of therapeutic agents
View Patent ↗The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
1. A cationic lipid of Formula I having the following structure:
or salts thereof, wherein:
R 1 and R 2 are either the same or different and are independently an optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, or R 1 and R 2 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;
R 3 is either absent or is hydrogen (H) or a C 1 -C 6 alkyl to provide a quaternary amine;
R 4 and R 5 are either absent or present and when present are either the same or different and are independently an optionally substituted C 1 -C 10 alkyl or C 2 -C 10 alkenyl; and
n is 0, 1, 2, 3, or 4.
2. The cationic lipid of claim 1 , wherein R 4 and R 5 are both butyl groups.
3. The cationic lipid of claim 1 , wherein R 1 and R 2 are both methyl groups.
4. The cationic lipid of claim 1 , wherein R 3 is absent.
5. The cationic lipid of claim 1 , wherein n is 1.
6. The cationic lipid of claim 1 , having the structure:
7. A lipid particle comprising a cationic lipid of claim 1 .
8. The lipid particle of claim 7 , wherein the particle further comprises a non-cationic lipid.
9. The lipid particle of claim 8 , wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol.
10. The lipid particle of claim 8 , wherein the particle further comprises a conjugated lipid that inhibits aggregation of particles.
11. The lipid particle of claim 10 , wherein the conjugated lipid that inhibits aggregation of particles comprises a polyethyleneglycol (PEG)-lipid conjugate.
12. The lipid particle of claim 10 , wherein the particle further comprises a therapeutic agent.
13. The lipid particle of claim 12 , wherein the therapeutic agent is a nucleic acid.
14. The lipid particle of claim 13 , wherein the nucleic acid is an interfering RNA.
15. The lipid particle of claim 14 , wherein the interfering RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate dsRNA, a small hairpin RNA (shRNA), and mixtures thereof.
16. A pharmaceutical composition comprising a lipid particle of claim 12 and a pharmaceutically acceptable carrier.
17. A method for introducing a therapeutic agent into a cell, the method comprising:
contacting the cell with a lipid particle of claim 12 .
18. A method for the in vivo delivery of a therapeutic agent, the method comprising:
administering to a mammal a lipid particle of claim 12 .
19. A method for treating a disease or disorder in a mammal in need thereof, the method comprising:
administering to the mammal a therapeutically effective amount of a lipid particle of claim 12 .
20. The method of claim 19 , wherein the disease or disorder is selected from the group consisting of a viral infection, a liver disease or disorder, and cancer.